Maud Eijkenboom, PhD (Maths/Physics), MSc (Psychology), is the Managing Director of Lixa, an Australian biotechnology company developing scalable, nontraditional antimicrobials with a mission to solve antimicrobial resistance (AMR) for anyone, anything, anywhere. Lixa's early clinical-stage resistance breakers aim to reverse resistance in MDR planktonic and biofilm bacterial infections, making first-line antibiotics, biocides and anti-septics work again across human health, agribusiness, and industrial markets. Maud is a passionate biotech leader with 30 years international discovery, R&D, commercialisation and business building experience within multinational pharmaceutical, listed and private biotech companies. In 2017, her son became unwell with a chronic, recalcitrant polymicrobial infection, leaving him bedridden and unable to attend school for over 7 years. Since then she has been committed to find solutions for the core of the AMR crisis. Maud is also a fervent advocate for raising AMR awareness together with key AMR influencers across the globe. She has spoken publicly across Australia and internationally about the need for greater public awareness of AMR.